Archive for the ‘Gene Therapy Research’ Category

PISCATAWAY, N.J. , July 8, 2013 /CNW/ - GenScript, the world's largest provider of synthetic genes, has aided a leading biopharmaceutical company, Novavax, Inc. (NVAX), in developing an avian influenza A/H7N9 vaccine candidate, by synthesizing three constructs containing genes that encode for key vaccine proteins in just 6 business days. On May 10, 2013 , Novavax announced that its vaccine candidate was developed and entered into pre-clinical trials in only 28 days, less than 6 weeks after initial reports of H7N9 infections on April 1 .

The manufacture of the constructs used in Novavax's H7N9 vaccine candidate was powered by GenScript's Rush Gene Service , which synthesizes gene sequences in as few as 4 days. GenScript also offers free gene sequence optimization, which is advantageous for the production of vaccines and protein-based biologics. Normally, it takes researchers using traditional laboratory methods two weeks or more to assemble constructs like those used to produce an H7N9 vaccine. However, as demonstrated by the rapid development of Novavax' vaccine candidate, the combination of gene optimization, rush gene synthesis and custom cloning, facilitated by GenScript's one-stop service platform, can drastically reduce assembly time, accelerating research and development.

"Our mission is to save lives by helping scientists accelerate their research. In this case, our Rush Gene Services are the perfect example of our commitment to our mission," said GenScript CEO Frank Zhang , Ph.D. "The progress made by scientists at Novavax on its H7N9 vaccine candidate in such a short time is the reason why we are dedicated to providing high-quality services on a daily basis."

About GenScript

Founded in 2002, GenScript is a leading biology CRO specializing in customized biology research services including gene and peptide synthesis, protein expression, antibody generation and drug discovery/development. GenScript is headquartered in Piscataway, NJ , has subsidiaries in Europe , Japan , and China , and has over 1,300 employees, who are dedicated to providing biology research services to 86 countries worldwide. Learn more at http://www.genscript.com.

About Novavax

Novavax, Inc. (NVAX) is a clinical-stage biopharmaceutical company creating vaccines to address a broad range of infectious diseases worldwide. Using innovative recombinant nanoparticle technology, and efficient manufacturing approaches, Novavax produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and respond to rapidly spreading infections. Learn more at http://www.novavax.com.

SOURCE: GenScript USA Inc.

Excerpt from:
GenScript's Rush Gene Services Help Novavax Expedite 28-day Development of H7N9 Vaccine

VEDBAEK, Denmark, July 8, 2013 (GLOBE NEWSWIRE) -- Exiqon A/S (EXQ.CO), a leading supplier of high-value products for gene expression analysis, today announced that Frost & Sullivan has recognized Exiqon as the recipient of the 2013 Company of the Year Award in Global microRNA Research Tools in light of the excellence that Exiqon has exhibited in the microRNA research space. This award follows Frost & Sullivan's most recent analysis of the global microRNA research tools and services market.

Exiqon was one of the first companies to commercially serve the microRNA market and scientists around the world have published thousands of peer-reviewed scientific papers based on Exiqon's microRNA research products since the first product introductions in 2005.

Most recently, Exiqon has developed a database search tool, miRSearch, which allows customers to do simple and intuitive searches across a dozen relevant databases and easily navigate the overwhelming amount of microRNA information when designing experiments. The search tool is accessible at http://www.exiqon.com/mirsearch. This recent extension complements Exiqon's leading miRCURY LNA(tm) products for microRNA research that include validated microRNA products for sample extraction, gene expression and functional analysis, as well as advanced software for data analysis.

Exiqon has been cited as a preferred one-stop shop provider of complete workflow solutions pertaining to microRNA research. Provision of microRNA profiling and screening services along with products has not only simplified purchasing, but has also attracted new customers for Exiqon.

"Over the past eight years, the microRNA research space has evolved from an exotic research field to an emerging market which includes validated biomarkers and clinical applications," says Exiqon CEO Lars Kongsbak. "According to Frost & Sullivan analysis, Exiqon holds an average market share of 24 percent, thereby continuing to be instrumental in helping scientists across industry and academia understand and apply the biology of microRNAs".

Frost & Sullivan does not accept nominations or submissions for Frost & Sullivan Awards. The selection of this Award comes through in-depth interviews and primary market analysis conducted by Frost & Sullivan's industry analyst team.

Additional information from Exiqon

Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)

Additional information from Frost & Sullivan

Mireya Espinoza, Frost & Sullivan, Corporate Communications - North America, tel.: 210. 247.3870 (fax: 210.348.1003, e-mail: mireya.espinoza@frost.com)

Read the original post:
Exiqon Awarded Global microRNA Research Tools Company of the Year by Frost & Sullivan

By Dr. Gregory Jicha special to the Herald-Leader

A new gene variant has been linked to Alzheimer's disease, and this association is strongest among elderly blacks.

Though not the first gene to be linked to the condition, the identification of this gene variant is a breakthrough, as it reveals another way Alzheimer's may be triggered in the brain.

We in the medical profession have known for a long time that blacks over the age of 65 have a greater chance of developing Alzheimer's disease than do Caucasians the same age. Researchers have identified a gene (ABCA7) that helps explain this increased risk, according to a recent report in the Journal of the American Medical Association. The report, based on a large government-funded study, not only sheds new light on why blacks are at increased risk for the disease, but also offers a possible new focus of research in the battle against Alzheimer's.

ABCA7 is linked to production and metabolism of cholesterol and lipids. We have known for years that vascular problems stemming from high cholesterol and atherosclerosis seem to increase the risk of Alzheimer's disease. This discovery supports previous evidence that vascular health may be a particular contributor to the development of Alzheimer's among blacks. But we have also seen evidence that Alzheimer's is influenced by other genes, as well as by environmental factors and lifelong health habits. Taking this new evidence into consideration, it appears that there may be multiple mechanisms that control the onset and progression of this devastating disease.

From this evidence, it appears that there are variations of Alzheimer's disease, with different causes much like different types of cancer. If this is true, the treatment an individual receives may need to be tailored to the particular variant of the disease that they have. At this time, it is not recommended that individuals seek genetic testing for Alzheimer's because the relationship between the gene variants and the disease has not been firmly established. Many people have an associated gene variant, but do not go on to develop Alzheimer's.

Approximately five million people in the U.S. have Alzheimer's disease; this number is expected to more than triple by the year 2050, when the disease will cost $1.1 trillion annually. According to the Alzheimer's Association, it is the only disease among the top ten killers that has no effective treatment.

The discovery of ABCA7 provides us with a clear strategy for trying to reduce the risk for Alzheimer's in all of us, but most importantly for blacks. It shows the need to control your cholesterol and vascular risk factors. At the UK Alzheimer Disease Center/Sanders-Brown Center on Aging, we have recently been awarded two National Institute of Health grants focused on doing exactly this. These two studies are looking for volunteers with or without memory problems that want to lower their risk for Alzheimer's disease.

For more information on how you can get involved, please call Sarah at (859) 323-1331. Start lowering your risk today.

Dr. Jicha is the McCowan Endowed Chair in Alzheimer Research at the UK Sanders-Brown Center on Aging.

More:
Gene discovery offers new path for Alzheimer's research

Genetic engineering- Kinetic typography
There #39;s a lot of dispute over whether we should be changing the DNA to produce a certain feature or to even experiment with animals to only potentially lead ...

By: Oenaiwolf

Read the original here:
Genetic engineering- Kinetic typography - Video

In 2008, my 19-year-old daughter, Danielle, took the same type of DNA test for breast and ovarian cancer that actress Angelina Jolie took recently.

Jolie, 38, came out positive and opted for a preventive double mastectomy to dramatically reduce her risk of breast cancer, a too-often-lethal disease. She based her decision on a telltale pattern of mutations in the BRCA1 gene and a family history of breast cancer that claimed her aunt at age 61 and ovarian cancer that took her mothers life at 56.

The actress was told she had an 87 percent chance of developing breast cancer and a 50 percent chance of getting ovarian cancer, because of her particularly potent combination of family-illness history and genetics. This risk assessment, however, offered a level of genetic certainty for Jolie that is regrettably rare for most healthy people wanting to know if they have an elevated predisposition for a common disease like breast cancer. Only a few thousand breast-cancer patients in the United States share Jolies specific genetic mutations. The rest of the more than 230,000 cases annually diagnosed nationwide are caused by different genes or by other factors that cannot be as accurately predicted.

Danielle was tested for this unusual genetic signature in BRCA1 as part of a project I initiated over a decade ago as a journalist writing about genetics. At the time the $3 billion Human Genome Project was nearing completion, and hype about how the science of genomics would revolutionize medicine, allowing researchers to tailor drugs to specific diseases, made headlines. Pharmaceutical and biotech companies dreamed of big profits in personalized medicine, and ethicists worried about how people would react to their prospective risks to diseases and face the sort of difficult choices that Jolie did.

To better understand the complexities of DNA and wanting to humanize what could be eye-glazing science for non-geneticists, I had sections of my own DNA decoded first for a story published inWiredin 2002, and later for other stories and a book. My personal DNA odyssey culminated in 2011 when I got the entirety of my genome sequencedall six billion As, Ts, Cs and Gs. The idea was to see what this information could tell a healthy person about his or her future. My daughter, who seems to suffer from the same curiosity geneas yet unidentifiedas I do, insisted that she be tested alongside my parents and me as part of what became a family exploration to investigate three generations of one familys genetics.

As a father, I didnt like this idea at all. Testing myself and my parents, was one thing. They were in their late 70s and quite healthy, as I was in my 40s. This suggested that we didnt have anything dreadful in our DNA. But my daughter was a different case. Our family has a history of breast and ovarian cancers. My paternal grandmother survived breast cancer in her 50s and died of ovarian cancer at 86. I also knew from my previous testing that I am a carrier of gene markers other than BRCA1 that are associated with breast and ovarian cancers, as is my father, even though as males we had no risk of getting ovarian cancer, and a very low risk for breast cancer.

What if we found something amiss in Danielles genome, especially something we could do nothing about? Its bad enough to discover that you have a high chance of developing a disease without a cure, like Alzheimers, when youve had a long life behind you. Its quite another to receive information that casts a shadow over your future when youre young.

Another fear was that we would find out something that required us to make a difficult decision. Jolie faced the wrenching choice of either living with an 87 percent certainty of getting breast cancer in the future or removing her healthy breasts now. We were all anxious about the possibility of having to choose to pay a terrible price if we found out Danielle was at high risk for getting cancer or another serious disease.

I held my breath and ordered a scan of hundreds of thousands of Danielles genetic markers through a DNA testing company based in Iceland called deCODE Geneticswhich has since ceased offering this service. In addition, I ordered from Utah-based Myriad Genetics an earlier version of the BRCA1 test that was later taken by Jolie.

Thankfully, my daughters results on the Myriad test were negative, although this ruled out only one rare possibility that she might get these dreadful diseases. Later, Danielle did test positive for other DNA markers implicated in breast and ovarian cancersmarkers associated with several gene mutations that can contribute to a persons disease risks and chances for survival.

Link:
My family’s decade in genetic limbo

Home Mail News Sports Finance Weather Games Groups Answers Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo! Home Video Photos GMA Year in Review LiveRoom Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials The Lookout Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Lookout The Sideshow Around the World Katie's Take Power Players This Could Be Big Newsmakers Trending Now Just Explain It The Upbeat Local Popular Search Keyword News Search Featured Videos Photos Just Explain It Katie's Take Weather The Upbeat Newsmakers

Excerpt from:
MPM Capital Invests $3 Million, Takes Minority Stake in InformedDNA

The Chemical Imbalance, Genetics Biology of Bipolar Disorder: Myths of Psychiatry
http://www.bipolarorwakingup.com Most, if not all of what most people think about the relationship between genetics, chemical imbalance theory and bipolar di...

By: bipolarorwakingup

Read the original post:
The Chemical Imbalance, Genetics

AUSTRALIAN Texel breeders could have the opportunity to sell their genetics to New Zealand studs.

Eight New Zealand Texel studs will be attending this years Australian Sheep and Wool Show in a bid to learn more about Australian genetics.

Australian Texel Stud Breeders Association president Peter Russell said the Texel breed were the feature breed at this years show attracting the New Zealand studs to Australia.

I met some New Zealand breeders when I was judging at the Canterbury Show in Christchurch last year, Mr Russell said.

We spoke about the national showing and they were intrigued.

Now a group of them, about 15 people representing eight studs are coming across.

Mr Russell said Texel genetics were usually bought in from Europe but this would be a good opportunity for Australian breeders to show the attributes of their genetics.

The Australian Sheep and Wool Show will be held in Bendigo from July 19-21.

Originally posted here:
Texels studs to showcase genetics

LOS ANGELES, July 8, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has recently executed a provider contract with Blue Cross and Blue Shield of Illinois. Blue Cross and Blue Shield of Illinois has 7.4 million members, most of whom are located in the State of Illinois.

With the execution of this agreement, oncologists and pathologists affiliated with this health plan now have the ability to more easily offer Response Genetics' suite of molecular predictive testing for their patients battling lung, colon, gastric, and melanoma cancers. Response Genetics' tests provide treating physicians with actionable information that help enable the best therapy to be employed for each individual patient. The personalized medicine inherent in Response Genetics' testing services brings with it a value proposition that is expected to improve patient outcomes and as a result enhance efficiencies in health care delivery.

The contract with this Blue Cross Blue Shield Association affiliate complements Response Genetics' existing managed care network and gives the CLIA-licensed lab access to millions of additional Blue Cross Blue Shield-insured members located primarily in Illinois and the Midwestern United States. Blue Cross and Blue Shield of Illinois is the oldest and largest health plan based in Illinois.

About Blue Cross and Blue Shield of Illinois

Blue Cross and Blue Shield of Illinois ("BCBSIL"), a division of Health Care Service Corporation, a Mutual Legal Reserve Company, is the largest health insurance company in Illinois. Started in 1936, BCBSIL remains member owned rather than publicly traded and is committed to promoting the health and wellness of its members and its communities, fostering greater access to care, and working to lower the overall cost of care while improving the health care quality and patient outcomes.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX(R) products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

Read more:
Response Genetics, Inc. Announces Contract With Blue Cross and Blue Shield of Illinois

Dallas, Texas (PRWEB) July 07, 2013

The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the world's leading healthcare companies:

Trends in gene therapy partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Gene therapy partnering contract documents Top gene therapy deals by value

The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals (http://www.reportsnreports.com/reports/262461-gene-therapy-partnering-terms-and-agreements.html). The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2007 including financial terms where available including over 300 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law?

The report also includes numerous tables and figures that illustrate the trends and activities in gene therapy partnering and dealmaking since 2007.

Visit link:
Gene Therapy Partnering Deals & Agreements By Healthcare Companies Analyzed in New Research Report at ReportsnReports ...

Goodie Mobb- Cell Therapy (1995)
From their album, Soul Food.

By: MRSOWELLMUSIC

View post:
Goodie Mobb- Cell Therapy (1995) - Video

Manila, Philippines -- Philippine Medical Association (PMA) President Dr. Leo Olarte said yesterday Filipinos need not go abroad or seek foreign consultation if they want to undergo stem cell therapy to cure an ailment.

Olarte warned of the risks and complications involved in stem cell therapy when improperly administered, citing the case of a government official who complained of feeling weak after the procedure was performed on him by a group of foreign medical team inside a posh hotel in Mandaluyong City.

The PMA chief said there are local experts who are capable of performing safe and reliable stem cell treatments in the country using the patient's own stem cells.

The other day, a lawyer for Dangerous Drugs Board (DDB) Chairman Antonio Villar faced the media and revealed that her client is filing charges against the foreign medical team who performed the procedure on him.

Lawyer Claire Pagayanan said the lead doctor who performed the stem cell therapy was from Germany while the other two doctors and nurses who assisted him were from Thailand.

Villar reportedly paid 15,000 euros or approximately P1.2 million for the procedure.

"Doctors who perform this therapy should be licensed by the Philippine Food and Drugs Administration. Before foreign doctors could perform here, they should apply for a license from the Professional Regulation Commission," he said. Those who fail to do so will be in "clear illegal practice of medicine in violation of the Medical Act of 1959," Olarte added.

For his part, PMA spokesperson Dr. Mike Aragon lamented how colonial mentality has affected the decision-making process of some Filipinos. "Maybe they are not well-informed about stem cell therapy, or it is the colonial mentality. Many of us think that if it is foreign, it is something good," Aragon said.

In the country, the only Department of Health (DoH)-approved stem cells that can be used for treatment are the patient's own stem cells harvested from his or her blood, bone marrow and fat.

Read the original:
Stem cell therapy can be done in PH — PMA President

Rochester, NY (PRWEB) July 06, 2013

A new study showed that loneliness and depression increases the level of chronic stress, which in turn hurts the immune system. The weakened immune system fails to control the latent herpes virus. The latent herpes virus reactivates and causes an outbreak.

Loneliness has been thought of in many ways as a chronic stressor a socially painful situation that can last for quite a long time. Lisa Jaremka, Institute for Behavioral Medicine Research, Ohio State University (1)

The study showed that lonely and depressed people produced more inflammation-related (viral) proteins in response to acute stress than did people who felt more socially connected. (1)

In addition, These (viral) proteins signal the presence of inflammation, and chronic inflammation is linked to numerous conditions, including coronary heart disease, Type 2 diabetes, arthritis and Alzheimers disease, as well as the frailty and functional decline that can accompany aging. (1)

As you can see, these latent viruses cause more than just herpes outbreaks. They underlie the inflammation, which causes many chronic diseases. Obviously people need ways to deal with loneliness and depression, but they also need something that targets latent viruses. Gene-Eden-VIR, a natural antiviral remedy, completely fills that need. - Mike Evans, polyDNA

Since the latent herpes virus reactivation has been linked to loneliness and depression, polyDNA recommends killing the herpes virus as soon as possible to help prevent the onset of an outbreak. Gene-Eden-VIR boosts the immune system and helps it attack and eliminate the latent herpes virus. A recent post marketing clinical study showed that Gene-Eden-VIR is safe and effective. Up to 70% of those studied reported a decrease in viral symptoms. (2)

Each ingredient of Gene-Eden-VIR was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent form of herpes. (3)

To learn more about Gene-Eden-VIR and herpes, visit http://www.gene-eden-kill-virus.com/Herpes-Remedy.php. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

Reference:

More:
Study: Loneliness and Depression May Activate the Latent Herpes Virus; polyDNA Recommends Gene-Eden-VIR Against the ...

WEDNESDAY, July 3 (HealthDay News) -- Thousands of sequences that control genes are active in the development of human limbs, a new study says.

The findings don't determine the exact genetic mechanisms that control development of limbs, but do provide the first genome-wide view of candidates to analzye, the researchers said.

"We now have a parts list that may account for these biological changes," study senior author James Noonan, an associate professor of genetics at the Yale School of Medicine, said in a university news release.

He and his colleagues compared gene regulatory sequence activity that occurs in humans, rhesus monkeys and mice during limb development in the womb. While activity was generally similar in all three species, certain regulatory sequences were active only in humans.

The study was published online July 3 in the journal Cell.

Noonan plans to transfer some of gene regulatory elements specific to humans into mice to see what aspects of human limb development they may control.

"It has been difficult to understand how human traits evolved, because we didn't have any idea where the important genetic changes might be," Noonan said. "Now we do, and we have the experimental tools to determine what biological effects these changes may have. Our study also provides a roadmap for understanding other human-specific traits that arise during development, such as increased brain size and complexity."

-- Robert Preidt

Copyright 2013 HealthDay. All rights reserved.

SOURCE: Yale University, news release, July 3, 2013

Go here to read the rest:
Scientists Make Genetic Discoveries About Limb Development

Moviestorm Machinima Creepy Genetics Lab from Libertaria
Used a combination of Bryce textures and primitives in Moviestorm (machinima software) to create this creepy shot of a genetics lab gone wrong. I used giant spiderwebs for the tendrils. Download...

By: Sabrina Pena Young

Read the original:
Moviestorm Machinima Creepy Genetics Lab from Libertaria - Video

Genetics and Weight Management
Genetics and Weight Management.

By: PreventSI

Go here to read the rest:
Genetics and Weight Management - Video

The Truth About Abs: They Aren #39;t Worth It (Genetics, Beginners, Pop Tarts)
[WEAR CHEF BUFF APPAREL] http://raskolapparel.com/ [FOLLOW ME ON INSTAGRAM] http://instagram.com/omarisuf/ [JOIN US ON MY FACEBOOK ARMY] http://www.facebook.com/chefbuff [MY FEMALE WORKOUT...

By: OmarIsuf

Read the original:
The Truth About Abs: They Aren't Worth It (Genetics, Beginners, Pop Tarts) - Video

Risks and benefits of stem cell therapy
Tony Velasquez and Karmina Constantino talk to Philippine Stem Cell Society founding member president of Philippine Academy of Aesthetice Academy Dr. Levi John Lansangan and Philippine Medical...

By: ANCalerts

Read more here:
Risks and benefits of stem cell therapy - Video

Experience in Stem Cell Therapy
#3588; #3640; #3603; #3649; #3614; #3607; #3652; #3604; #3657; #3649; #3594; #3619; #3660; #3611; #3619; #3632; #3626; #3610; #3585; #3634; #3619; #3603; #3660; #3649; #3621; #3632; #3612; #3621; #3621; #3633; #3614; #3608; #3660; #3607; #3637; #3656; #3588; #3640; #3603; #3649; #3617; #3656; #3588; #3640; #3603; #3649; #3614; #3607; #3652; #3604; #3657; #3619; #3633; #3610; #3585; #3634; #3619; #3619; #3633; #3585; #3625; #3634; #3650; #3604; #3618; #3585; #3634; #3619; #3593; #3637; #3604; Stem Cell #3651; #3609; #3591; #3634; #3609; "Thailand Innovative Medical Tourism" #3607; #3637; #3656; #3592; #3633; #3604; #3586; #3638; #3657; #3609; #3651; #3609; #3623; #3633; #3609; #3648; #3626; #3634; #3619; #3660; #3607; #3637; #3656; 29 #3617; #3636; #3606;...

By: Pat R

Read the original:
Experience in Stem Cell Therapy - Video

Rochester, NY (PRWEB) July 05, 2013

A study showed that Cytomegalovirus (CMV) may accelerate the progression of a certain form of brain cancer. The study was conducted by researchers at the Ohio State University Comprehensive Cancer Center and was published in the journal Cancer Research on June 27th 2013. (2)

CMV has been detected in many cancer types We believe that CMVs action occurs in the tumors cells of origin... Dr. Chang-Hyuk Kwon, the Ohio State University Comprehensive Cancer Center (1)

Dr. E. Antonio Chiocca, another study author said anti-viral therapy against CMV might now be justified for human cancers. (1)

Mike Evans of polyDNA noted that, We are not surprised by these findings. In fact, the studys results provide further evidence for the Theory of Microcompetition discovered by Dr. Hanan Polansky and discussed in his ground breaking book, Microcompetition with Foreign DNA and the Origin of Chronic Disease. Weve long believed that latent viruses like CMV are the underlying cause of many diseases. Targeting these viruses should be a core part of treatment. Our product, Gene-Eden-VIR is a natural remedy that does just that.

polyDNA is a leading producer of natural CMV remedies. By helping the body's immune system target the latent CMV virus, people also lower their risk of developing symptoms caused by the latent CMV virus. A recent post marketing clinical study showed that Gene-Eden-VIR is effective against latent viruses. (3)

Each ingredient of Gene-Eden-VIR was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent form of the Cytomegalovirus. (4)

To learn more about Gene-Eden-VIR, visit http://www.gene-eden-kill-virus.com.

References:

(1)http://www.healthcanal.com/cancers/39493-cytomegalovirus-might-speed-brain-cancer-growth.html (2)http://www.ncbi.nlm.nih.gov/pubmed/23811943 (3)http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php (4)http://gene-eden-kill-virus.com/studies.php

Read more:
Study: Cytomegalovirus (CMV) May Accelerate Brain Cancer; polyDNA Recommends Gene-Eden-VIR Against Latent CMV

Genetic switches flipped in the growing brain may explain how thinking and behaviour changes between birth and adolescence, new research suggests.

Signals that turn genes on or off change dramatically during childhood, altering the way neurons communicate, scientists have found.

The process, known as DNA methylation, affects the activity of genes but not the genetic code itself.

Recent studies have shown a possible link between the same mechanism and serious mental disturbances including schizophrenia, bipolar disorder and depression.

The blueprint of switching signals that determine the activity of genes is known as the "epigenome".

Scientists found that in the frontal cortex, the part of the brain that most determines how we think and act, the epigenome is transformed between birth and the end of adolescence.

In both mice and humans, DNA methylation progressively increased until entry into adulthood, the research showed.

Dr Ryan Lister, from the University of Western Australia, a member of the team whose findings are reported in the journal Science, said: "The human brain has been called the most complex system that we know of in the universe.

"So perhaps we shouldn't be so surprised that this complexity extends to the level of the brain epigenome.

"These unique features of DNA methylation that emerge during critical phases of brain development suggest the presence of previously unrecognised regulatory processes that may be critically involved in normal brain function and brain disorders."

See the original post:
Gene signals 'may explain changes'

07/04/2013 20:05 INDIA Indian doctor: London stop the new eugenics, it is immoral and dangerous by Nirmala Carvalho The UK is set to legalize in vitro fertilization with three parents: the fetus will thus have the DNA of three different people. For a member of the Pontifical Academy of Life, approval of such testing is likely to pave the way for "improper use of the medicine and transformation of genetic selection into a real option." In India, surrogacy has become a million dollar industry.

Mumbai (AsiaNews) - "Creating designer babies is alarming, immoral and dangerous. These experiments are a return of eugenics" says Pascoal Carvalho, a doctor in Mumbai and member of the Pontifical Academy for Life. Commenting on the news that UK the is about to become the first country in the world to legalize in vitro fertilization with three different donors: the mother, the father and a "donor" to AsiaNews he says "human genetic engineering is a reality and that the science of eugenics has now been validated beyond question - it has definite potential for being misused." ."

According to British researchers working on the project, in "three way" invitro fertilization eliminates the so-called "mitochondrial diseases", a series of genetic defects transmitted only from mother to child. The female egg is composed of a core, inside which is located the mitochondrion, organelle that provides energy during the cell multiplication, which will then form the fetus in all its parts (organs, tissues, muscles, etc.).. In case of problems with the mitochondria, the energy necessary for the development of cells in an embryo is reduced, thus giving rise to possible defects in the fetus. However, the mitochondrion itself does not determine the physical or genetic characteristics of the embryo.

Dr. Carvalho, who has obtained a degree in Immunology, explains how in vitro fertilization with three donors works. In this IVF treatment, the mitochondria of the original egg is removed if there is a defect, and replaced by mitochondria from a healthy woman, minimising the chances of genetically-transmitted birth defects". At this point the egg "compound" is fertilized with the sperm of the father. The problem, notes the doctor, "is that even though most of the DNA is located in the chromosomes of the nucleus, the mitochondria also has a 'its' DNA, known as 'mitochondrial DNA'." This genetic material "contains 37 genes, all essential to the proper functioning of mitochondria. For this reason, some features of the 'third parent' could be passed on".

Carvalho, who is also a member of the diocesan commission for human life, specifies: "Thousands of embryos will need to be produced and experimented upon in developing these techniques. The destruction of embryos in the IVF process requires the destruction of human which is sacred." "Besides - he said - certain limits have already been exceeded. We are already witness to moving boundaries with other IVF-related technologies, IVF already allows doctors to do genetic testing prior to implantation. Gender selection is possible, and with further technical refinements genetic "enhancements" might become an option."

In vitro fertilization is much debated in India, which has become a destination for medical tourism for years thanks to a vague regulation on the subject. In particular, surrogacy is increasingly widespread in the country: legalized by the Supreme Court in 2002, today it is a million dollar industry. In Mumbai alone there are between 70 and 80 centers for assisted reproduction and just over 200 in the State of Maharashtra. Recently, Shah Rukh Khan, a Bollywood superstar, and his wife had their third child through a surrogate mother, opening a major debate across the country.

See more here:
07/04/2013 20:05 INDIA Indian doctor: London stop the new eugenics, it is immoral and dangerous

Main tank

By: DNA Genetics

See more here:
Main tank - Video

100l Fry tank
secret technique on how to boost microwomrs culture for nearly nothing.

By: DNA Genetics

Continue reading here:
100l Fry tank - Video

Genetics of Complex Diseases with Prof Nick Martin Part 2
This is the first #39;Where Is Science Heading? #39; presentation at the University of Queensland, presented on May 14, 2013. Senior scientist Prof Nick Martin, from the Queensland Institute of Medical...

By: Luke Sartor

View post:
Genetics of Complex Diseases with Prof Nick Martin Part 2 - Video